Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of ROTAVAC 5D in Chilean Infants
NCT05958771Phase 3Completed
- Sponsor
- Universidad de Chile
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rotavirus gastroenteritis comparing ROTAVAC 5D with Placebo (2 arms). Primary endpoint: Percentage of subjects who suffer a severe rotavirus gastroenteritis according to the Vesikari Score. Started Jul 2023; status: completed.
02
Drugs
rotavirus vaccine (live attenuated, oral)
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT05958771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958771.